Moderna on Monday announced its experimental vaccine against Covid-19 was shown to be 94.5 percent effective according to early results from a clinical trial with more than 30,000 participants.
“This positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent COVID-19 disease, including severe disease,” said Stephane Bancel, Moderna’s CEO.
For more news your way, download The Citizen’s app for iOS and Android.
Download our app and read this and other great stories on the move. Available for Android and iOS.